A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 170 (planned)
- Started
- May 6, 2026
- Main results expected
- Feb 16, 2028
- Fully finished
- Feb 16, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events (AEs)
Measured over: Up to 90 days from last dose or study discontinuation
Number of Participants With AEs Leading to Treatment Discontinuation
Measured over: Up to 90 days from last dose or study discontinuation
Number of Participants With Serious Adverse Events (SAEs)
Measured over: Up to 90 days from last dose or study discontinuation
Number of Participants With AEs Leading to Death
Measured over: Up to 90 days from last dose or study discontinuation
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07415031 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC